Sen Li, Hengrui Zhang, Ying Wang, Qunhui Wang, Ruizi Ren, Yuan Gao et al. Second‐Line Treatment of ES‐SCLC in the Immunotherapy Era: An Exploratory Real‐World Study. // Cancer Medicine. – 2026. – DOI: 10.1002/cam4.72512. – URL: https://onlinelibrary.wiley.com/doi/10.1002/cam4.72512?af=R
Sen Li, Hengrui Zhang, Ying Wang, Qunhui Wang, Ruizi Ren, Yuan Gao, Baohua Lu, Fei Qi, Mingming Hu, Yong Zhang, & Tongmei Zhang (2026). Second‐Line Treatment of ES‐SCLC in the Immunotherapy Era: An Exploratory Real‐World Study. Cancer Medicine. https://doi.org/10.1002/cam4.72512
Sen Li, et al. “Second‐Line Treatment of ES‐SCLC in the Immunotherapy Era: An Exploratory Real‐World Study.” Cancer Medicine, 2026. doi:10.1002/cam4.72512.
@article{Li2026,
title = {Second‐Line Treatment of ES‐SCLC in the Immunotherapy Era: An Exploratory Real‐World Study},
author = {Li, Sen and Zhang, Hengrui and Wang, Ying and Wang, Qunhui and Ren, Ruizi and Gao, Yuan and Lu, Baohua and Qi, Fei and Hu, Mingming and Zhang, Yong and Zhang, Tongmei},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72512},
url = {https://onlinelibrary.wiley.com/doi/10.1002/cam4.72512?af=R}
}